Icon Plc (ICLR) — Analysis Summary
Icon Plc (ICLR) has a market cap of $13.03B with year-over-year revenue growth of -0.4%. Net margin stands at 2.8%. The stock trades at a P/E ratio of 56.8.
Key Takeaways
- Revenue changed -0.4% year-over-year
- Net margin of 2.8%
- P/E ratio of 56.8
Compared with its sector, ICLR posted revenue growth of -0.4% and trades at a P/E of 56.8.
Icon Plc (ICLR)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Debt/EBITDA at 4.1x — elevated leverage
Interest coverage at 2.2x — limited headroom for earnings decline
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Employees
40,100
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.